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Reduced Myelin Signal in normal-
appearing White Matter in 
neuromyelitis optica Measured by 
7T Magnetic Resonance Imaging
i-Jun chou1,2,3, Radu tanasescu1,4, Olivier E. Mougin5, Penny A. Gowland5, 
Christopher R. tench1, William P. Whitehouse2, Bruno Gran  1, Esmaeil nikfekr1, 
Basil Sharrack6, Gordon Mazibrada7 & Cris S. constantinescu1
Whether the integrity of normal-appearing white matter (NAWM) is preserved in neuromyelitis optica 
spectrum disorders (NMOSD) is open to debate. To examine whether the tissue integrity of NAWM in 
NMOSD is compromised compared to that in healthy controls and patients with multiple sclerosis (MS), 
we prospectively enrolled 14 patients with NMOSD, 12 patients with MS, and 10 controls for clinical 
functional assessments and quantitative imaging, including T1 relaxation time (T1) and magnetization 
transfer ratio (MTR) at 7 Tesla. Cognitive performance on the Paced Auditory Serial Addition Test with 
a 3-second interstimulus interval (PASAT-3) was significantly lower in the NMOSD compared to the 
MS group (mean number of correct answers, 34.1 vs. 47.6; p = 0.006), but there were no differences in 
disease duration or disability. Histograms of T1 and MTR maps of NAWM demonstrated a decreased 
peak height in patients with NMOSD compared to the healthy controls, but not compared to patients 
with MS. Using 7T quantitative magnetic resonance imaging (MRI), this study showed that the NAWM 
in patients with NMOSD is abnormal, with reduced myelin signal; this was not previously observed 
using MRI at a lower field strength.
Neuromyelitis optica spectrum disorders (NMOSD) are rare but debilitating conditions with an estimated prev-
alence of 0.52 to 4.4 per 100,000 population1. Classic NMO is characterized by optic neuritis and longitudi-
nally extensive transverse myelitis (LETM)2. NMOSD initially presents as a limited form of optic neuritis or 
LETM, whose diagnosis can be supported by a positive serological test of autoantibodies against aquaporin-4 
(AQP4)3. The term NMOSD encompasses classic NMO and cases with or without autoantibodies against AQP44. 
Approximately a quarter of AQP4 seronegative NMOSD patients have antibodies against myelin oligodendrocyte 
glycoprotein (MOG)5. NMOSD are associated with reduced quality of life and increased mortality.
Many patients with NMOSD exhibit normal brain magnetic resonance imaging (MRI) findings at diagnosis, 
despite the fact that cavitation, suggesting a necrotizing process, is frequently found histologically in lesions in 
the medulla oblongata, spinal cord, and optic nerves6,7. Whether normal-appearing white matter (NAWM) on 
imaging studies for NMOSD is indeed normal is still open to debate. The magnetization transfer ratio (MTR) 
of NAWM at 1.5 Tesla (T) did not differ between NMOSD and healthy controls8,9. The diffusion tensor imaging 
(DTI) at 3T revealed abnormalities confined to the optic and corticospinal tracts10,11. In contrast, patients with 
multiple sclerosis (MS) have multiple brain white matter (WM) lesions, where demyelination and remyelina-
tion is the characteristic histological finding12. Both lesions and NAWM in MS patients have been quantified 
using quantitative T1 mapping and MTR, with demyelination, inflammation, oedema and tissue disorganisation 
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being assessed histopathologically12–15. In addition, at 7T, both quantitative T1 mapping and the MTR can detect 
changes within NAWM in clinically isolated syndromes and relapsing-remitting MS (RRMS) relative to healthy 
controls16 via imaging with submillimetre resolution. Quantitative imaging at 7T is capable of revealing the dam-
aged substrate within WM lesions and NWAM in NMOSD.
Based on aforementioned MRI and histological findings, we hypothesized that (1) the extent of structural 
change of WM lesions in NMOSD is more severe than in MS, but that (2) the integrity of NAWM in NMOSD is 
less compromised than in MS. Therefore, we prospectively enrolled patients with NMOSD, patients with MS, and 
healthy participants and acquired brain MRI images at 7T, for comparison of the measured T1 relaxation time 
and MTR maps among the groups.
Results
Patient characteristics. We prospectively investigated 36 participants: 14 patients with NMOSD, 
12 patients with MS, and 10 healthy participants. Ten (71%) of the patients with NMOSD had classic NMO 
(Supplementary Table 1). Eight (67%) of the patients with MS had RRMS, two (17%) had secondary progressive 
MS (SPMS), and two (17%) had primary progressive MS (PPMS).
The date of the MRI scan was separated from a clinical attack by at least 30 days. One of the patients with 
NMOSD was treated with corticosteroids alone, and the others received long-term immunosuppressants: five had 
azathioprine, five had rituximab, and three had mycophenolate mofetil; of these patients, three combined their 
treatment with low-dose corticosteroids. Four patients with MS received long-term immunomodulatory agents: 
one used interferon beta-1a, one glatiramer acetate, one natalizumab, and one dimethyl fumarate.
Clinical assessments. Clinical characteristics and functional assessment results are summarized in Tables 1 
and 2, respectively. There were no significant differences in disease duration, Expanded Disability Status Scale 
(EDSS) score, self-administered Fatigue Severity Scale (FSS) score, quantitative functional test results of leg func-
tion/ambulation (Timed 25-Foot Walk), or arm function (9-Hole Peg Test) between the patients with MS and 
NMOSD. However, cognitive function (Paced Auditory Serial Addition Test with a 3-second interstimulus inter-
val, PASAT-3) was significantly lower in the patients with NMOSD than in MS patients (mean number of correct 
responses, 34.1 vs. 47.6, respectively; p = 0.006). The Multiple Sclerosis Functional Composite (MSFC) scores 
derived by summing the three aforementioned components were similar between the NMOSD and MS patients. 
The scores were significantly worse in NMOSD and MS patients than in controls except for cognitive function 
(PASAT-3), which was similar between the patients with MS and controls. In healthy controls, age was only neg-
atively correlated with hand function score (rho = −0.665, p = 0.036).
MRI. Lesions. Lesion count and volume, and the quantitative T1 and MTR of the lesions were measured 
in each subject. The lesion count and volume were significantly higher in patients with MS than in those with 
NMOSD or healthy controls (Table 3). The lesions were mainly localized in the supratentorial regions of patients 
with MS, and in the infratentorial regions of patients with NMOSD. A few incidental, small and nonspecific 
lesions in the supratentorial deep WM were identified in four controls. The lesions in the patients with MS had a 
significantly higher measured T1 than those in patients with NMOSD or controls. Similarly, MS lesions had the 
lowest mean lesion MTR value, followed by NMOSD lesions. There was a correlation between mean T1 and mean 
MTR for the lesions in patients with NMOSD (Spearman’s rho = −0.800, p = 0.001) and for those of patients with 
MS (rho = −0.912, p < 0.001).
In the patients with NMOSD, the mean lesion T1 was negatively correlated with cognition score 
(rho = −0.592, p = 0.033). In the patients with MS, lesion volume was positively correlated with disease duration, 
and negatively correlated with hand function score.
NAWM. The T1 and MTR were calculated for the NAWM and histogram metrics were used to asses this, to 
increase power by comparing the whole region of interest (ROI). The results are shown in Table 4, and averaged 
histograms are shown in Fig. 1. The heights of the peaks of both the T1 and MTR histograms of the NAWM of the 
NMOSD
(n = 14)
MSa
(n = 12)
Controls
(n = 10) P
Median age, years (IQR) 54.0 (37.0–63.0) 55.5 (40.5–63.5) 44.5 (24–57) 0.416
Female, n (%) 10 (71) 7 (58) 7 (70) 0.769
Presence of serum Ab, n (%) NMO-IgG/AQP4: 8 (57)MOG: 1 (7) n/a n/a
Median disease duration, years (IQR) 8 (3.0–11.0) 13 (7.5–20.5) n/a
Receiving immunosuppressants or 
immunomodulatory agents, n (%) 14 (100)
b 5 (42)c n/a .
Table 1. Comparisons of demographic and clinical characteristics between the patients with NMOSD, patients 
with MS and healthy controls. Abbreviations: Ab, antibody; AQP4, aquaporin 4; IgG: immunoglobulin G; IQR, 
interquartile range; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; NMO, neuromyelitis 
optica; NMOSD, neuromyelitis optica spectrum disorders; n/a, not applicable or not available; SD, standard 
deviation. aEight (67%) MS patients had relapsing remitting MS, two (17%) had secondary progressive MS, and 
two (17%) had primary progressive MS.
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NMOSD patients were significantly lower than those in the healthy subjects, but were not different from those 
of the patients with MS. The peak position was not statistically different among the three groups; however, in the 
patients with MS, the 25th percentile MTR value was lower than that for the healthy participants. This pattern 
indicates that there are focal areas of abnormality rather than diffuse abnormality within the voxels.
In the patients with MS, T1 histogram metrics were correlated with MSFC score, and MTR histogram metrics 
were correlated with leg function score using Spearman’s rank correlation coefficient (Table 5). No such correla-
tions were noted in the patients with NMOSD.
Lesion volume and NAWM. In the patients with NMOSD, both the T1 and MTR histogram metrics of the 
NAWM were correlated with lesion volume. No such correlation was found in the patients with MS.
NMOSD
(n = 14)
MS
(n = 12)
Controls
(n = 10) P
Median EDSS and FSS (IQR)
   EDSS
5.25 (4.0–6.0) 6.0 (4.0–6.5) n/a
n = 12 n = 12 n = 10
   FSS 5.6 (5.3–6.3)A 6.0 (4.9–6.4)A 2.1 (1.2–2.6)B <0.001*
Mean MSFC raw score and z-scorea (±SD)
T25-FWb n = 11 n = 12 n = 10
   Raw score, s 8.56 ± 2.46A 9.98 ± 4.14A 4.59 ± 0.30B <0.001*
   Z-score −13.40 ± 8.31A −17.69 ± 14.56A 0 ± 1B <0.001*
9HPT n = 14 n = 12 n = 10
   Raw score dominant hand, s 34.83 ± 24.79A 27.83 ± 4.80A,B 17.60 ± 1.93B 0.044*
   Raw score nondominant handc, s 86.48 ± 199.24 31.85 ± 12.10 19.95 ± 2.75 0.375
   Z-score of both hands −3.89 ± 2.00A −3.42 ± 1.20A 0 ± 1B <0.001*
PASAT-3d n = 13 n = 10 n = 10
   Raw score (correct number/60) 34.15 ± 10.58 A 47.60 ± 10.29B 52.00 ± 6.68B <0.001*
   Z-score −2.67 ± 1.58 A −0.66 ± 1.54 A 0 ± 1B <0.001*
MSFC sum score n = 10 n = 10 n = 10
   Z-scoree −6.72 ± 2.84 A −6.05 ± 4.8A 0 ± 0.57B <0.001*
Table 2. Comparisons of EDSS, FSS, and MSFC between the 14 patients with NMOSD, 12 patients with MS, 
and 10 healthy controls. Abbreviations: EDSS, Expanded Disability Status Scale; FSS, Fatigue Severity Scale; 
IQR, interquartile range; MSFC, Multiple Sclerosis Functional Composite; MS, multiple sclerosis; n/a, not 
applicable or not available; NMOSD, neuromyelitis optica spectrum disorders; PASAT-3, Paced Auditory 
Serial Addition Test with a 3-second interstimulus interval; SD, standard deviation; T25-FW, Timed 25-
Foot Walk Test; 9HPT-dominant, 9-Hole Peg Test of the dominant hand. A,B,CThe same character indicates 
no difference between groups, while a different character indicates a difference. aA z-score is a standardized 
number, in this study representing how close a test result is to the mean of 10 healthy controls and expressed 
as a standard deviation. A negative z-score indicates that the test result was worse than the mean performance 
of the 10 healthy controls, and the value indicates the number of standard deviations. bThe T25-FW could not 
be performed in two patients with NMOSD because of limited physical ability, and was not completed in one 
patient with NMOSD because of physical fatigue. cOne subject with NMOSD was unable to perform the test on 
the non-dominant hand because of limited physical ability, so a value of 777 seconds was applied as suggested by 
the MSFC scoring manual. dOne patient with NMOSD and two with MS refused to perform the PASAT-3 test 
because they stated that they did not understand the principle of the test. eThe MSFC sum Z score was calculated 
for subjects who completed all tests by combining the three components into a single z score.
NMOSD
(n = 14)
MS
(n = 12)
Controls
(n = 10) P
Lesion count
(median, IQR)
11A
(2.0–18.0)
74B
(33.5–112.5)
0A
(0.0–3.0)# <0.001*
Lesion volume (mm3)
(median, IQR)
242.4A
(60.7–696.0)
5217.0B
(2356.8–9488.2)
0A
(0–27.2)# <0.001*
T1 relaxation time (ms)
Mean ± SD 1869 ± 367
A 2163 ± 268B 1511 ± 117A 0.003*
MTR (%)
Mean ± SD 38.8 ± 6.5
A 32.0 ± 4.6B 46.5 ± 3.8C <0.001*
Table 3. Comparison of lesion load, T1 relaxation time and MTR among the NMOSD patients, MS patients 
and healthy controls. Abbreviations: IQR, interquartile range; MS, multiple sclerosis; MTR, magnetization 
transfer ratio; NMOSD, neuromyelitis optica spectrum disorders; SD, standard deviation. #Among the 10 
healthy controls, 4 had incidental findings of at least one nonspecific white matter lesion. A,B,CThe same 
character indicates no difference between groups, while a different character indicates difference.
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Discussion
This study used high-resolution 7T MRI to compare the T1 and MTR of intracranial lesions and NAWM among 
NMOSD patients, MS patients, and healthy controls. Compared to MS lesions, the NMOSD lesions showed less 
obvious tissue changes. Regarding the NAWM, NMOSD patients had a lower histogram peak height for both 
T1 and MTR compared to controls. None of the histogram metrics were significantly different from those of the 
patients with MS although there was a trend towards the NMOSD measures differing less from those of the con-
trols compared to the MS patients, similar to the trends in changes observed in the lesions. The decreased peak 
height of NAWM in both the MS and NMOSD patients indicated that at least some of the NAWM in the patients 
with NMOSD was abnormal, as has been shown in patients with MS. The histogram metrics for the NAWM were 
correlated with lesion volume in the patients with NMOSD, but not in those with MS. Taken together, our study 
suggests that the NMOSD lesions had less myelin damage than the MS lesions, and that the NAWM in patients 
with NMOSD is abnormal, where the abnormal changes were correlated with lesion volume.
T1 is an intrinsic biophysical property of tissue, and is primarily determined by water binding to macromol-
ecules, including myelin. In MS, increased T1 of the WM is highly associated with reduced structural integrity, 
and black holes (the darkest area on T1 weighted images) have the highest T113. An elevated T1 correlates with 
a loss of myelin, axons14 and increased free water, which to some extent reflects gliosis by virtue of the increase 
in water protons17. Magnetization transfer (MT) imaging measures proton exchange between free protons and 
macromolecular bound protons and provides a relatively accurate measurement of the myelin content12,18. Our 
MS results for the lesions were similar to those observed in previous studies, reflecting decreased myelin content 
and tissue integrity, which can be due to demyelination or incomplete remyelination12,15.
Our results showed an abnormal mean MTR, but not T1, in the lesions of patients with NMOSD. However 
the deviation from normal was smaller than in the patients with MS. Our findings reject the first hypothesis. In 
contrast to previous histopathological findings of focal necrosis in autopsied patients with fulminant NMO6,7, 
the patients with NMOSD in the current study had fewer destructive lesions in the brain overall than those with 
MS. One possible explanation for this is that our patients with NMOSD benefited from effective treatment such 
as plasma exchange, immunosuppressants or B cell depletion therapy. Another possibility is lesion heterogeneity, 
as the standard deviation of lesion T1 and MTR in NMOSD patients, was as wide as that in MS patients, and 
several types of lesions have been reported in NMOSD6,19. The histopathological hallmark of the active lesions 
of NMOSD patients with AQP4 antibodies is loss, or decreased staining, of AQP4 protein, and an absence of 
astrocytes or loss of astrocyte distal processes19, thus disrupting the cerebrospinal fluid (CSF)-brain barrier and 
blood-brain barrier, and leading to necrosis6,20. Nevertheless, the early active lesions in NMOSD patients showed 
relative preservation of myelin compared to those of MS patients19. However, these changes may not contribute 
sufficient water to account for the observed changes measured by T1, because other alterations, such as infiltra-
tion of eosinophils or granulocytes, have also been observed6. Furthermore, the patients with MS in this study 
had a relatively longer disease course than those with NMOSD; as such, tissue destruction of chronic lesions may 
be more obvious in MS. Overall, our results seem to be compatible with the known pathological characteristics of 
primary astrocytopathy occurring in NMOSD, and primary demyelination occurring in MS21.
In this study, histogram metrics were used to assess the NAWM to provide maximum power to detect changes. 
The histogram metrics were statistically indistinguishable between the NMOSD and MS patients, rejecting the 
second hypothesis. Regarding the T1 histogram of patients with PPMS, the peak height decreased and the peak 
position increased; therefore, the histogram metrics shifted rightwards over 2 years22. If myelin was reduced in 
the NAWM, the histogram metrics would shift leftwards, such that the peak height and peak position would both 
decrease. Previous studies have shown that abnormalities in MS NAWM are subtype-dependent23: SPMS shows 
NMOSD
(n = 14)
MS
(n = 12)
Controls
(n = 10) P
T1 relaxation time (mean ± SD)
Peak height (10–3 pixels) 5.9 ± 1.5A 5.6 ± 1.2A 6.8 ± 1.0B 0.067*
Peak position (ms) 1244 ± 43 1265 ± 47 1264 ± 25 0.915
25th percentile (ms) 1203 ± 40 1217 ± 31 1218 ± 27 0.990
50th percentile (ms) 1259 ± 49 1282 ± 37 1265 ± 23 0.604
75th percentile (ms) 1321 ± 64 1353 ± 55 1312 ± 22 0.204
MTR (mean ± SD)
Peak height (10-3, pixels) 7.7 ± 1.5A 6.7 ± 1.3A 8.9 ± 1.0B 0.002*
Peak position (%) 55.8 ± 3.4 54.2 ± 3.2 56.2 ± 3.8 0.401
25th percentile (%) 51.5 ± 2.9 A 49.3 ± 3.3B 52.5 ± 3.5A 0.081*
50th percentile (%) 55.4 ± 3.1 53.9 ± 2.9 55.7 ± 3.6 0.400
75th percentile (%) 59.1 ± 3.3 58.4 ± 3.0 58.9 ± 3.8 0.926
Table 4. Comparisons of the NAWM histogram metrics, as indexed by T1 relaxation time or MTR, among 
the NMOSD patients, MS patients and healthy controls. The mean values of five parameters for each group 
(the height and position of the histogram peak and the 25th, 50th and 75th percentile values) were included in 
the analysis. Abbreviations: NMOSD, neuromyelitis optica spectrum disorders; MS, multiple sclerosis; MTR, 
magnetization transfer ratio; SD, standard deviation. A,B,CThe same character indicates no difference between 
groups, while a different character indicates a difference.
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changes in both the peak position and height of NAWM histograms, whereas RRMS and PPMS show decreased 
height only23–25. Since our study included more patients with RRMS and PPMS, a change in NAWM peak location 
was not observed. However, our patients with MS showed a decrease in the peak height of both the T1 and MTR 
NAWM histograms, suggesting a decreased proportion of normal WM. The results also revealed a decreased 
proportion of normal WM in patients with NMOSD compared to controls.
The results of the current study are in line with previous DTI studies of changes in the microstructural diffu-
sivity of WM tracts in optic tracts, medulla oblongata, and corticospinal tracts8,10,11, and provide further evidence 
of reduced myelin content in the NAWM of NMOSD patients, based on myelin content-specific MT imaging. 
DTI, a tool for investigating the microstructural diffusivity of WM tracts, revealed abnormalities in optic tracts, 
the corpus callosum, the medulla oblongata, and corticospinal tracts in NMOSD patients8,10,26–28. DTI at 3T 
showed greater diffusivity changes in the NAWM of 93 patients with NMOSD compared to 43 healthy controls, 
and the extent of DTI-detectable NAWM changes was less than that in 53 patients with MS11. Measuring changes 
in the diffusion of water in directional structures, such as nerve bundles, in the brain provides insights into the 
structural integrity, in terms of myelin and axonal content, of MS patients29,30. However, NAWM axons in patients 
with NMOSD seemed not to be affected, as measured by MR spectroscopy at 1.5T or 3T field strength16,31,32. 
Using MTR quantitative imaging at 1.5T field strength to evaluate the NAWM of NMO patients, two earlier 
Figure 1. The averaged histograms of the normal-appearing white matter (NAWM) in neuromyelitis optica 
spectrum disorder (NMOSD; blue) patients, multiple sclerosis (MS; red) patients and healthy controls (green). 
(a) T1 relaxation time (T1): the average peak height in the T1 histogram of the NAWM of NMOSD patients 
was significantly lower than that in healthy subjects and did not differ from that in MS patients, reflected in 
the greater width of the NMOSD and MS histograms. The peak position was not statistically different among 
the three groups. (b) Magnetization transfer ratio (MTR): The average peak height in the MTR histogram of 
the NAWM of NMOSD patients was significantly lower than that in healthy subjects and did not differ from 
that in MS patients, reflected in the relative widths of these frequency histograms. The peak position was not 
statistically different among the three groups, but in MS patients, the 25th percentile value for MTR was lower 
than in healthy participants.
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studies did not find altered MTR parameters8,33. However, using 7T MRI, we found evidence of changes in myelin 
in the NAWM of patients with NMOSD.
The abnormal findings in the NAWM of the patients with NMOSD noted in this study appear to be robust, 
because they were shown by two different MRI techniques based on different physical principles. MTR at 
1.5T failed to distinguish the NAWM between NMOSD and controls, in terms of either mean values or peak 
heights8,33. However, using 7T MRI, we found evidence of abnormal myelin and water content in NAWM, and 
this change was correlated with lesion volume mainly localized in the infratentorium. We assume that we were 
able to detect MTR changes because of the ultra-high field strength. It is possible that the difference in spatial 
resolution between our study and those using lower field strengths made it easier to observe smaller changes 
in NAWM herein. This could be verified by repeating the 7T scanning at the spatial resolution used in previous 
lower field strength studies. Histopathological studies to clarify the current findings pertaining to the NAWM are 
also warranted. Nevertheless, the current study did not find an association between cognition and MRI parame-
ters. This may be attributed to the small number of patients and the mixture of NMOSD subtypes.
Several limitations of the current study deserve discussion. First, the number of patients included was small. 
We intentionally included different MS subtypes, based on prior knowledge of the likelihood of NAWM abnor-
malities, to match for disability levels. However, the mixture of phenotypes may have introduced bias, including 
in the cognition measures. Second, lesion detection was performed using MTsat (MTR based on proton- and 
T2*-weighted imaging with presaturation to water) images, which might not be as accurate as 3T fluid-attenuated 
inversion recovery (FLAIR) images. However, we previously showed that 7T-MTsat sequences detected most of 
Lesion NAWM T1 relaxation time NAWM MTR
Volume Mean T1
Mean 
MTR
Peak 
height
Peak 
position p25 p50 p75
Peak 
height
Peak 
position p25 p50 p75
NMOSD
Disease duration −0.228 −0.104 0.009 0.320 −0.300 −0.283 −0.369 −0.413 0.205 0.384 0.501 0.426 0.340
EDSS −0.206 −0.048 −0.170 −0.213 −0.327 −0.347 −0.191 −0.041 −0.183 0.052 0.141 0.177 0.219
FSS −0.392 −0.332 0.513 0.612* −0.173 −0.138 −0.330 −0.448 −0.144 0.443 0.415 0.429 0.416
MSFC-z score 0.454 0.021 0.112 0.022 0.514 0.590 0.436 0.239 0.106 −0.094 −0.175 −0.255 −0.312
T25-FW-z score 0.405 0.033 0.092 −0.019 0.479 0.524 0.390 0.220 −0.014 0.030 −0.050 −0.090 −0.113
9HPT-z score −0.299 0.415 −0.134 0.065 −0.199 −0.189 −0.168 −0.137 0.120 0.433 0.385 0.374 0.308
PASAT3-z score 0.325 −0.592* 0.332 0.093 0.048 −0.077 −0.139 −0.198 −0.003 −0.031 0.040 0.031 0.059
Lesion volume 1 −0.080 −0.173 −0.263 0.715** 0.604* 0.611* 0.516 0.147 −0.584* −0.542* −0.587* −0.553*
Lesion mean T1 −0.080 1 −0.800** 0.169 −0.006 0.057 0.017 −0.034 0.473 −0.014 0.044 −0.083 −0.216
Lesion mean 
MTR −0.173 −0.800** 1.000 0.184 −0.254 −0.237 −0.293 −0.274 −0.404 0.307 0.216 0.312 0.391
MS
Disease duration 0.639* 0.054 −0.266 0.498 −0.029 −0.044 −0.103 −0.161 0.347 −0.597* −0.301 −0.499 −0.591*
EDSS 0.375 0.377 −0.211 −0.204 0.202 0.169 0.374 0.453 0.007 −0.195 −0.137 −0.123 −0.082
FSS 0.190 −0.126 0.188 −0.019 −0.113 0.029 0.219 0.356 −0.012 −0.034 −0.062 0.028 0.132
MSFC-z score −0.465 −0.134 −0.014 0.634* −0.886** −0.710* −0.813** −0.842** −0.193 0.512 0.446 0.482 0.505
T25-FW-z score −0.498 −0.236 0.120 0.310 −0.253 −0.329 −0.568 −0.638* 0.057 0.644* 0.588* 0.606* 0.525
9HPT-z score −0.828** −0.414 0.520 −0.088 −0.204 −0.317 −0.452 −0.468 −0.075 0.299 0.231 0.243 0.219
PASAT3-z score −0.174 0.014 −0.009 0.722* −0.406 −0.248 −0.303 −0.318 0.529 0.320 0.377 0.251 0.152
Lesion volume 1 0.217 −0.467 0.333 0.373 0.267 0.288 0.210 0.463 −0.299 −0.057 −0.229 −0.367
Lesion mean T1 0.217 1 −0.912** −0.351 0.003 0.105 0.307 0.431 −0.331 −0.071 −0.205 −0.085 0.051
Lesion mean 
MTR −0.467 −0.912** 1.000 0.141 −0.037 −0.053 −0.204 −0.300 0.148 0.060 0.119 0.061 −0.007
Healthy controls
FSS −0.572 0.047 −0.060 0.049 0.024 0.022 −0.082 −0.046 −0.038 −0.028 −0.020
MSFC-z score 0.244 0.336 −0.106 −0.082 −0.236 −0.398 −0.054 0.010 −0.044 −0.045 −0.051
T25-FW-z score 0.441 0.444 0.035 0.158 0.016 −0.155 0.322 −0.506 −0.509 −0.527 −0.543
9HPT-z score −0.093 0.452 0.270 0.254 0.106 −0.184 0.168 0.246 0.279 0.243 0.197
PASAT3-z score 0.066 −0.324 −0.486 −0.552 −0.524 −0.338 −0.582 0.276 0.155 0.208 0.259
Lesion volume 1 0.060 −0.128 −0.202 −0.270 −0.337 0.081 −0.207 −0.285 −0.283 −0.287
Table 5. Correlation coefficients of MRI metrics of normal-appearing white matter, lesion parameters and 
clinical factors. *Correlation significant at the 0.05 level (2-tailed). **Correlation significant at the 0.01 
level (2-tailed). Abbreviations: EDSS, Expanded Disability Status Scale; FSS, Fatigue Severity Scale; MSFC, 
Multiple Sclerosis Functional Composite; MS, multiple sclerosis; MTR, magnetization transfer ratio; NMOSD, 
neuromyelitis optica spectrum disorders; PASAT-3, Paced Auditory Serial Addition Test with a 3-second 
interstimulus interval; p25, 25th percentile; p50, 50th percentile; p75, 75th percentile; T1, T1 relaxation time; 
T25-FW, Timed 25-Foot Walk Test; 9HPT, 9-Hole Peg Test.
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the WM lesions identified by 3T-FLAIR sequences, and missed only approximately 1.5% of small lesions34; hence, 
patients do not need to undergo both 7T and 3T scans on the same day. Third, the temporal lobes were not all 
included because the signal loss caused by inhomogeneity in the applied transmit radiofrequency (RF) field at 
high field strength was more pronounced in these regions.
Furthermore, the NAWM map included supratentorial, basal ganglia and infratentorial regions, where pathol-
ogy of the basal ganglia and infratentorial brain might be different from that of supratentorial areas; further stud-
ies are needed to clarify this. Nevertheless, the current study was strengthened by the piloting of two quantitative 
methods based on 7T MRI, used to compare two groups of patients matched for demographic characteristics and 
level of disability.
conclusions
Our analysis of T1 and MTR values suggested that the lesions in the NMOSD patients had decreased myelin sig-
nal, but the changes therein were less pronounced compared to those in the patients with MS, in turn suggesting 
that they were less myelin-destructive. 7T MRI demonstrated a decreased peak height of NAWM histograms in 
NMOSD patients compared to controls. However, the histogram metrics were statistically indistinguishable from 
those in the patients with MS, suggesting that at least part of the NAWM in the patients with NMOSD was indeed 
abnormal, with reduced myelin, which had not been previously observed using MRI at a lower field strength.
Methods
This study was approved by our local Research Ethics Committee (REC), and by the relevant National Health 
Service (NHS) Research & Development (R&D) department (REC reference: 13/EM/0080). The research was 
performed in accordance with relevant guidelines and regulations. Informed consent was obtained from all 
participants.
Patients. Consecutive patients with NMOSD referred to the Neuroimmunology Clinic of University Hospital 
Nottingham, between July 2013 and November 2014, were enrolled at the Sir Peter Mansfield Imaging Centre 
(SPMIC) at the University of Nottingham. Patients were eligible if (1) they had a diagnosis of NMOSD4 or MS35 as 
assessed by specialists, and (2) they were clinically stable, fully conscious and orientated. Age- and sex-matched 
patients with MS were recruited simultaneously. We used posters to recruit healthy volunteers, who were inter-
viewed by a neurologist. The exclusion criteria included claustrophobia, metal objects or devices implanted in the 
body, and pregnancy. The patients were assessed using the EDSS, MSFC, and FSS. Healthy volunteers were only 
assessed with the MSFC and FSS.
MRI image acquisition. All participants underwent MRI scanning using a 7T Philips Achieva (Philips 
Medical Systems, Best, The Netherlands) with whole-body gradients. The scanner was equipped with a 32-channel 
head-only parallel imaging sensitivity encoding (SENSE) receiver coil and a head-only volume quadrature RF coil 
(Nova Medical, Inc., Wilmington, MA, USA). The parameters of the MRI sequences are detailed in Supplementary 
Table 2, and the techniques used have been detailed previously36–39. Briefly, whole brain three-dimensional (3D) 
phase-sensitive inversion recovery (PSIR) images (spatial resolution = 0.6 × 0.6 × 0.6 mm3) were acquired and 
segmented to obtain a WM mask39. Then, 3D magnetization-prepared rapid gradient echo (MPRAGE) sequences 
with seven inversion times were acquired (spatial resolution = 1.25 × 1.25 × 1.25 mm3) and processed to produce 
quantitative measurements of T138. In addition, MT images were acquired for quantitative measurement of MTRs 
derived from two raw images: MTnosat (proton- and T2*-weighted imaging with no presaturation), and MTsat 
(presaturation to water) (spatial resolution = 0.6 × 0.6 × 0.6 mm3)36,37. MTsat imaging was also used to identify 
lesions. The scanning protocol included a B1 map to correct the MT images for the effects of B1 inhomogeneity.
Post-processing. Firstly, we obtained a lesion mask for each subject. Lesions were visually identified and 
outlined on MTsat using a semi-automated seed-growing technique, implemented in the in-house NeuRoi soft-
ware (http://www.nottingham.ac.uk/scs/divisions/clinicalneurology/software/neuroi.aspx). The lesions were 
identified in all image slices, which covered the supratentorium, midbrain, rostral pons, and part of the cerebel-
lum. The total volume of these lesions was then calculated, and a binary lesion mask was generated using NeuRoi.
Secondly, we obtained the NAWM mask. Initially, a WM probability map was segmented from PSIR images 
using an automatic segmentation process, implemented in Statistical Parametric Mapping software (SPM8; http://
www.fil.ion.ucl.ac.uk/spm/), with a threshold value of 0.95 to generate a binary WM mask. Next, a lesion-free 
WM mask was generated by applying the lesion masks. Subsequently, the lesion-free WM mask was eroded by 
three voxels to exclude any partial volume effects at the grey matter-WM junctions, lesion-WM or CSF-WM 
borders to generate the NAWM mask38.
Thirdly, T1 and B1-corrected MTR maps were generated based on the raw images for each subject on a 
pixel-by-pixel basis. The T1 map was generated using formula (1)40,41:
α=



−



− 





M M exp T
T
1 1
1 (1)0
The MTR map was generated using formula (2):
=
−MT MT
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MTR ( )
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Finally, the T1 and B1-corrected MTR maps were combined with the lesion and NAWM masks, to yield lesion 
and NAWM maps for each subject (Fig. 2). All voxels of NAWM with an MTR of less than 10% were excluded 
from the analysis to effects of image noise and CSF signals42. All of the acquired images for a given subject were 
registered to the same space using FLIRT in FSL (available at www.fmrib.ox.ac.uk/fsl).
We compared lesion properties based on the mean values of the lesion maps. To detect subtle changes in 
NAWM, histogram metrics of the NAWM maps derived from each subject were normalized to the total voxel 
count to eliminate any effect of differences in NAWM volume among subjects. The bin size for NAWM is 1 ms for 
T1 and 0.1% for MTR. Five histogram parameters were extracted: the height and position of the histogram peak 
and the 25th, 50th and 75th percentile values.
Power calculation. We assumed that the peak height and position of the NAWM histogram of NMOSD 
patients were significantly different from those of healthy controls, because DTI imaging at 3T revealed diffusiv-
ity changes along optic and cortico-spinal tracts10,11. Because no quantitative T1 or MTR data of NAWM at 7T 
in NMOSD patients are available, we performed a pre-protocol power calculation based on data derived from 
a previous MS study38. We calculated the T1 of WM and peak heights for 9 patients with RRMS and 11 healthy 
controls. We predicted that the difference in NAWM histograms between patients with NMOSD and controls 
would be 40% of that between MS patients and controls. To determine the actual difference using a 2-tailed t-test, 
10 subjects per group were required for 85% power at a significance level of 0.05, with a medium effect size.
An anticipated difficulty for 7T MRI studies of NMOSD patients is recruitment of a sufficient num-
ber of patients to obtain acceptable quality images for analysis. Some patients were too severely disabled (e.g. 
bed-ridden, limb spasticity) or lived a long distance from the 7T suite at the University of Nottingham. We 
estimated the number of MS and NMOSD patients in England using the Clinical Practice Research Datalink 
(CPRD), which is a database focused on primary care in the UK, and linked to secondary care in England. The 
estimates showed that NMOSD is very rare in England, with a prevalence rate in 2012 of 3.7 per 100,000 people 
(Chou et al., unpublished). The prevalence of MS is 70 times higher than that of NMOSD. Hence, the recruitment 
target for each group was 10 subjects.
Statistical analysis. Comparisons of subgroups were performed using Fisher’s exact test for categorical data, 
the Mann-Whitney U test for ordinal (clinical rating scale) data, and ANOVA for continuous data. Multiple com-
parisons were conducted using the least significant difference (LSD) test, to identify which groups were different 
when ANOVA showed statistical differences among groups. Statistical significance was established with a cut-off 
level of 0.1. To assess correlations between clinical parameters and MRI-derived parameters (Table 5), Spearman’s 
rank correlation coefficient (rho) was used. All statistical tests were two-tailed, and all calculations were per-
formed using SAS software (version 9.4; SAS Institute, Cary, NC, USA); correlation coefficients were calculated 
using the SPSS software package (version 22; IBM Corp, Armonk, NY, USA).
Data Availability
All data generated or analysed during this study are included in this article or the Supplementary Information 
Files.
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